Nuvation Bio (NUVB) Stock Forecast & Price Target

Nuvation Bio is viewed positively because Ibtrozi has a differentiated, best-in-class profile in ROS1+ NSCLC, with strong durability, broad efficacy across clinically relevant subgroups, and no new safety signals in the latest pooled TRUST-I/II analyses. Safusidenib adds meaningful upside as the key value driver, supported by recent BTD momentum, a 79.1% 36-month PFS rate in Japanese patients, and ongoing studies that are positioned to capture the whole glioma opportunity with 2027 data still on track. Despite 3Q26 revenue of $27.5M coming in lighter than expected and the Ibtrozi launch needing more time, the company remains well capitalized and its two-asset valuation framework, with estimated contributions of about $8 from Ibtrozi and $11 from safusidenib, supports the bullish view.

Nuvation Bio is viewed negatively because Ibtrozi’s launch has already shown softness, with revenue of $27.5M missing both the $30.5M estimate and the Street’s $29.2M, while management attributed it to an unexpected 15% decline in the ROS1 TKI market. The business also faces a slow uptake profile, as new patient starts were flat at about 160 with fewer critical 1L adds near 100, suggesting patient stacking will take longer and launch variability may persist in a small, competitive indication. Beyond commercialization risk, the company’s valuation still depends heavily on unproven pipeline assets such as safusidenib, while financing needs, royalty obligations, and up to $100M of debt add pressure on future shareholder returns.